Presenting at CMSC 2022, researchers evaluated the relationship between attack severity with serum (s) GFAP and sNfL, and the effect of inebilizumab on attack severity and serum biomarkers.
Presenting at CMSC 2022, researchers evaluated whether racial patterns exist in NMOSD- and MOGAD-associated ON and the potential role of social disadvantage in these patterns.
Optic nerve enhancement patterns and white matter lesion distribution can guide diagnoses.
The FDA has accepted the Biologics License Application (BLA) for satralizumab (Genentech) for the treatment of neuromyelitis optica spectrum disorder.
A new anatomic threshold may be useful for identifying unilateral optic nerve lesions in patients with multiple sclerosis.
The advantages of oral prednisone include “being less expensive and more convenient to access and administer and [being] preferred by patients to [intravenous] methylprednisolone.”
Using the inter-eye percentage difference may help surpass limitations associated with device and proprietary segmentation algorithms.
Opicinumab may potentially enhance spontaneous remyelination after acute optic neuritis.
There were no significant associations for alternative risk factors after controlling for radiation dosage.
There was a significant association between the average GCIP thickness and MSFC scores.
